MYHEALTHCHECKED PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10 GBX | 0.00% |
|
-6.98% | -24.53% |
| Jan. 11 | MyHealthChecked expects 2023 earnings breakeven | AN |
| Jan. 11 | MyHealthChecked PLC Provides Revenue Guidance for the Full Year 2023 | CI |
| Sales 2021 | 16.38M 20.46M | Sales 2022 | 22.31M 27.87M | Capitalization | 12.29M 15.35M |
|---|---|---|---|---|---|
| Net income 2021 | 2M 2.5M | Net income 2022 | 1M 1.25M | EV / Sales 2021 | 0.69 x |
| Net cash position 2021 | 6.39M 7.98M | Net cash position 2022 | 7.56M 9.44M | EV / Sales 2022 | 0.21 x |
| P/E ratio 2021 |
8.7
x | P/E ratio 2022 |
8.29
x | Employees | 21 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.38% |
More Fundamentals
* Assessed data
More news
| 1 week | -6.98% | ||
| Current month | -18.37% | ||
| 1 month | -18.37% | ||
| 3 months | -13.04% | ||
| 6 months | -14.89% | ||
| Current year | -24.53% |
1 week
9.50
11.00
1 month
9.5013.00
Current year
9.5016.00
1 year
8.2629.99
3 years
8.2687.00
5 years
8.26111.72
10 years
8.26340.05
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 19-11-13 | |
Bhavika Patel
CTO | Chief Tech/Sci/R&D Officer | 37 | - |
| Director/Board Member | 66 | 22-04-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Adam Reynolds
CHM | Chairman | 59 | 16-02-16 |
Lyn Rees
BRD | Director/Board Member | 51 | 19-11-13 |
| Director/Board Member | 58 | 17-03-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 10 | 0.00% | 206,629 |
| 24-04-25 | 10 | 0.00% | 0 |
| 24-04-24 | 10 | -4.76% | 83,118 |
| 24-04-23 | 10.5 | -2.33% | 52,829 |
| 24-04-22 | 10.75 | 0.00% | 11,005 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am EDT
More quotes
MyHealthChecked PLC is a United Kingdom-based consumer home-testing healthcare company. The Company is the umbrella brand of a range of at-home rapid tests, as well as deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and blood sample collection kits. The Company also provides COVID tests. The Company's multi-platform portfolio of tests offers users access to a variety of test types, sample collection options, and levels of analysis, enabling it to meet diverse customer needs. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analyzed in partner laboratories for a range of biomarkers. The tests have been made available online and for over-the-counter purchase. All its business activity is underpinned by two distinct routes to market: business to business to consumer (B2B2C) and direct to consumer.
Calendar
2024-05-30
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.53% | 6.48M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- FRI Stock
